Philip Reilly is a Senior Strategic Advisor to the CDCN and a Venture Partner at Third Rock Ventures. Dr. Reilly is a highly respected clinical geneticist with an extensive track record of launching and building companies in the rare disease space. He joined Third Rock Ventures in 2009 to discover, launch and build companies pursuing breakthrough treatments for rare genetic diseases. He has played integral roles in several portfolio companies, including former interim CMO of Voyager Therapeutics, scientific advisory board member of bluebird bio and former interim CMO, co-founder and board member of Edimer, and former board member of Lotus Tissue Repair.
Phil is currently a trustee of Cornell University and is on the board of overseers of Weill Cornell Medical College. Prior to joining Third Rock, he was the chief executive officer and chairman of Interleukin Genetics, and before that, he was the executive director of the Eunice Kennedy Shriver Center for Mental Retardation. He served twice (2000 and 2003) as president of the American Society of Law, Medicine and Ethics. He is a founding fellow of the American College of Medical Genetics. He has authored or co-authored more than 100 articles in scholarly journals as well as several books about clinical genetics. Phil has held teaching positions at Tufts University School of Medicine and Harvard Medical School. Phil received his B.A. from Cornell University and holds an M.D. from Yale University, a J.D. from Columbia University, is a member of the Massachusetts Bar and is board certified in internal medicine and clinical genetics.